A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

NCT03381066 Phase 3 UNKNOWN

This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR mutations.

Details

Lead sponsor	Yonsei University
Phase	Phase 3
Status	UNKNOWN
Enrolment	225
Start date	2018-04-10
Completion	2022-12

Conditions

• Completely Resected NSCLC With Common EGFR Mutations

Interventions

• gefitinib, pemetrexed,cisplatin
• Vinorelbine, cisplatin

Primary outcomes

• disease-free survival — 5 years
  Time from the randomization to recurrence or any cause of death.

Countries

South Korea